secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2026-05-29T12:42:42+00:00
Accession:  0001213900-26-062458
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
--------------------------------------------------------------------------------

- Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.
- Cash and equivalents $8.8M, up from $5.0M at Dec 31, 2025; no debt or toxic financing.
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences (TATA Enterprise) for global ~$57B market.
- Filed Orphan Drug Designation application for VT-1953 with FDA; submitted proposals for pivotal development guidance.
- Raised $5.29M via sale of 1,089,545 shares at $5.00 (59.2% premium to prior close); ~15% dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/0001213900-26-062458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/ea0292643-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-062458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer